Revenue Recognition (Tables)

12 Months Ended

Dec. 31, 2019

Revenue from Contract with Customer [Abstract]

Disaggregation of revenue

Segment information for fiscal year 2019 is as follows (in thousands):

	Year Ended December 31, 2019
	Performance Enzymes		Novel Biotherapeutics		Total
Major products and service:
Product Revenue	$	29,465	$	—	$	29,465
Research and development revenue	28,691		10,302		38,993
Total revenues	$	58,156	$	10,302	$	68,458
Primary geographical markets:
Americas	$	13,039	$	—	$	13,039
EMEA	26,831		10,302		37,133
APAC	18,286		—		18,286
Total revenues	$	58,156	$	10,302	$	68,458

Segment information for fiscal year 2018 is as follows (in thousands):

	Year Ended December 31, 2018
	Performance Enzymes		Novel Biotherapeutics		Total
Major products and service:
Product Revenue	$	25,590	$	—	$	25,590
Research and development revenue	21,483		13,521		35,004
Total revenues	$	47,073	$	13,521	$	60,594
Primary geographical markets:
Americas	$	15,332	$	38	$	15,370
EMEA	8,878		13,483		22,361
APAC	22,863		—		22,863
Total revenues	$	47,073	$	13,521	$	60,594

Segment information for fiscal year 2017 is as follows (in thousands):

	Year Ended December 31, 2017
	Performance Enzymes		Novel Biotherapeutics		Total
Major products and service:	$	26,685	$	—	$	26,685
Product Revenue	15,648		7,691		23,339
Research and development revenue	$	42,333	$	7,691	$	50,024
Total revenues
Primary geographical markets:
Americas	$	15,575	$	—	$	15,575
EMEA	11,919		7,691		19,610
APAC	14,839		—		14,839
Total revenues	$	42,333	$	7,691	$	50,024

Contract with customer

The following table presents changes in the contract assets, unbilled receivables, contract costs, and contract liabilities for the years ended December 31, 2019 and 2018 (in thousands):

	Year Ended December 31, 2019
	Beginning Balance		Additions	Deductions (1)	Ending Balance
Contract Assets	$	35	12,073	(11,081)	$	1,027
Unbilled receivables, current	$	1,916	13,014	(4,831)	$	10,099
Unbilled receivables, non-current (2)	$	786	—	(786)	$	—
Contract Costs (2)	$	42	—	(42)	$	—
Contract Liabilities: Deferred Revenue	$	8,288	7,552	(13,796)	$	2,044

	Year Ended December 31, 2018
	Beginning Balance		Additions	Deductions (1)	Ending Balance
Contract Assets	$	—	8,934	(8,899)	$	35
Unbilled receivables, current	$	—	2,908	(992)	$	1,916
Unbilled receivables, non-current (2)	$	—	786	—	$	786
Contract Costs (2)	$	239	—	(197)	$	42
Contract Liabilities: Deferred Revenue	$	18,966	6,446	(17,124)	$	8,288

(1) The asset or liability balances are presented as a net position per contract and accordingly the deductions column includes the netting effect of presenting each contract on a net position basis as either a net liability or asset.

(2) Included in non-current assets in our consolidated balance sheets.

We recognized the following revenues (in thousands):

	Year Ended December 31,
Revenue recognized in the period for:	2019		2018
Amounts included in contract liabilities at the beginning of the period:
Performance obligations satisfied	$	4,567	$	13,615
Changes in the period:
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods	1,442		374
Performance obligations satisfied from new activities in the period - contract revenue	62,449		46,605
Total revenue	$	68,458	$	60,594

Performance obligation, expected timing of satisfaction

The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts (in thousands):

	2020		2021		2022		2023 and Thereafter		Total
Product Revenue	$	—	$	365	$	1,622	$	—	$	1,987
Research and development revenue	57		—		—		—		57
Total revenues	$	57	$	365	$	1,622	$	—	$	2,044